This book examines the regulatory framework for untested and unapproved (off-label) uses of medicines in the EU, UK and USA. While off-label uses may offer hope, they may also expose patients to risks and uncertainties. This work clarifies the regulatory mechanisms and litigation trends concerning off-licence prescriptions in these jurisdictions.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.